Novo’s unsolicited bid for Metsera challenges Pfizer pact

Novo’s surprise offer turns a quiet deal into a live auction

Novo Nordisk has thrown down the gauntlet with an unsolicited proposal to acquire Metsera, intensifying the pressure on Pfizer’s pending bid inked in September 2025. The move signals Novo’s intent to secure another GLP-1 foothold while testing rival resolve in a white-hot obesity market.

The core question now is whether Metsera’s board deems Novo’s offer a “Superior Proposal,” a designation that could trigger a match process and, potentially, a breakup fee. If Pfizer holds matching rights, the bid risks morphing into a rapid-fire auction with escalating price and tighter terms.

Novo Nordisk’s unsolicited bid puts Pfizer’s Metsera deal in jeopardy

Strategically, the rationale is straightforward, Metsera’s GLP-1 candidate MET-097i fits neatly within Novo’s cardiometabolic expansion while denying competitor a future asset. Third-party reports suggest Novo’s offer tops Pfizer’s earlier pact, citing a figure around $6.5 billion, underscoring how scarcity in differentiated obesity assets, inflating bid dynamics.

From Novo’s vantage point, the calculus mirrors themes deepen the GLP-1 bench, expand cardiometabolic optionality, and defend leadership as Eli Lilly scales its presence. Novo has spent the past years consolidating its dominance in metabolic care, from GLP-1 agonists to next-generation combination agents targeting obesity, NASH, and cardiovascular endpoints. Adding Metsera would reinforce that position with a differentiated mechanism and delivery platform, extending Novo’s reach beyond injectable formats into novel oral and hybrid regimens.

For Pfizer, the stakes are equally high. The company has been rebuilding its metabolic disease portfolio after discontinuing its earlier GLP-1 efforts and absorbing setbacks in oral obesity candidates. Its agreement to acquire Metsera, announced in September, was widely seen as a re-entry point one that could restore pipeline relevance and give Pfizer optionality across small-molecule and peptide delivery formats. Losing Metsera to Novo would not only erase that momentum but also leave Pfizer trailing competitors in a therapeutic area it once dominated.

The emerging rivalry underscores how the GLP-1 market has evolved from a product race to a platform contest. As Eli Lilly extends its dual and triple agonist programs deeper into cardiometabolic indications, both Novo and Pfizer are jockeying to secure assets that offer more than incremental benefit either in novel mechanisms or improved patient convenience. Whether Novo’s unsolicited bid succeeds or not, the move signals an escalating urgency among Big Pharma players to lock in long-term metabolic leadership before the next wave of combination therapies redefines the field.

Novo’s unsolicited proposal, valued at up to $77.75 per share or roughly $9 billion marks a significant premium of about 133% over Metsera’s pre-deal trading price. The two-step structure includes an immediate $56.50 per-share cash payment and a contingent value right (CVR) worth up to $21.25 per share based on future milestones. For Pfizer, which has been rebuilding its metabolic disease portfolio after discontinuing its earlier GLP-1 efforts, retaining Metsera would be central to maintaining pipeline relevance and optionality across small-molecule and peptide delivery formats. Losing Metsera to Novo would not only erase that momentum but also leave Pfizer trailing competitors in a therapeutic area it once dominated.

The emerging rivalry underscores how the GLP-1 market has evolved from a product race to a platform contest. As Eli Lilly extends its dual and triple agonist programs deeper into cardiometabolic indications, both Novo and Pfizer are jockeying to secure assets that offer more than incremental benefit—either in novel mechanisms or improved patient convenience. Whether Novo’s unsolicited bid succeeds or not, the move signals an escalating urgency among Big Pharma players to lock in long-term metabolic leadership before the next wave of combination therapies redefines the field.

Regulators will scrutinize any Novo outcome through an obesity lens. The FTC and European Commission have become more assertive on pharmaceutical roll-ups, and the GLP-1 category’s market concentration invites questions. Precedent shows deals can clear with conditions see Amgen–Horizon’s path though second requests or EU Phase II referrals could extend timelines.

Risks cluster around valuation, integration and clinical execution. A bidding war might overshoot fundamental value if MET-097i’s differentiation remains unproven. Post-close integration could stall development or partner optionality. And clinical risk remains central without pivotal data, value realization depends on readouts. Structuring toolsCVRs, milestone-based earnouts and development safeguards can temper those exposures.

Next, watch for a formal “Superior Proposal” determination and a defined match window, often measured in days, not weeks. Regulatory filings, including any HSR submission and early EU engagement, will telegraph deal confidence and pace. Program catalysts for MET-097i and competitor updates from Lilly and Pfizer will shape the negotiating backdrop. Bottom line, this is a fast-moving auction in a crowded policy lane, and the clock favours the bidder that marries price with certainty.

For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com.